Popular terms

[SEARCH]

Antagonist topics
Antagonist
Recurrence
Proliferative Disorder
Proliferative
Antibodies
Progesterone
Dicyclomine
Scopolamine
Extracellular
Pharmaceutically Acceptable Salt
Metalloprotein
Nucleic Acids
Polynucleotide
Nucleic Acid
Monoclonal

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Antagonist patents



      
           
This page is updated frequently with new Antagonist-related patent applications. Subscribe to the Antagonist RSS feed to automatically get the update: related Antagonist RSS feeds. RSS updates for this page: Antagonist RSS RSS



Date/App# patent app List of recent Antagonist-related patents
08/27/15
20150240842 
 Modular hinged joint for use with agonist-antagonist tensile inputs patent thumbnailnew patent Modular hinged joint for use with agonist-antagonist tensile inputs
A modular hinged joint which attaches to the end of a structural member converts agonist-antagonist tensile forces to either side of a cord into a torque in a second structural member. Plain bearing surfaces with hour-glass shaped profiles maintain the alignment of the joint tensile forces are applied to the cord.

08/27/15
20150239972 
 Methods for the treatment of infections and tumors patent thumbnailnew patent Methods for the treatment of infections and tumors
Pd-1 antagonists are disclosed that can be used to reduce the expression or activity of pd-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these pd-1 antagonists in conjunction with an antigen from the infectious agent or tumor.
Dana-farber Cancer Institute, Inc.


08/27/15
20150239958 
 Process for the modulation of the antagonistic activity of a monoclonal antibody patent thumbnailnew patent Process for the modulation of the antagonistic activity of a monoclonal antibody
The present disclosure relates to the antibody engineering field and, more particularly, to a process for the screening of antibodies and/or the modulation of the agonistic/antagonistic activity of antibodies. More particularly, the disclosure concerns a process of improving the antagonistic activity of a monoclonal antibody directed against a specific target molecule, or a divalent functional fragment or derivative thereof, the antibody being capable of inhibiting one or more of the biological activities of the target molecule, wherein the process comprises a stage of reconfiguration of the hinge region consisting of a modification of the amino acid sequence of the hinge region by the deletion, the addition or the substitution of at least one amino acid.
Pierre Fabre Medicament


08/27/15
20150239873 
 Substituted carbamate compounds patent thumbnailnew patent Substituted carbamate compounds
And pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (i) as well as pharmaceutical compositions containing such compounds.

08/27/15
20150238602 
 Combination therapies and uses for treatment of demyelinating disorders patent thumbnailnew patent Combination therapies and uses for treatment of demyelinating disorders
Methods and compositions for enhancing one or more of: myelination, re-myelination, oligodendrocyte numbers, or neuroaxonal protection, while ameliorating an inflammatory condition in a human subject are disclosed. In certain embodiments, the methods and compositions described herein include a reparative agent (e.g., a lingo-1 antagonist) and an immunomodulatory agent, in combination.
Biogen Idec Ma Inc.


08/27/15
20150238601 
 Treatment of ocular disorders patent thumbnailnew patent Treatment of ocular disorders
The invention provides methods of treatment of ocular disorders, including ocular disease with an angiogenic component. In certain embodiments, the treatment comprises administration of a rock2 inhibitor and an angiogenesis inhibitor.
Kadmon Corporation, Llc


08/27/15
20150238559 
 Methods of treating rheumatoid arthritis patent thumbnailnew patent Methods of treating rheumatoid arthritis
The present invention relates to methods for the treatment of rheumatoid arthritis. In particular, the present invention relates to methods of treating rheumatoid arthritis with gnrh antagonists in patients with high gonadotropin and/or gnrh levels..
Betanien Hospital


08/27/15
20150238558 
 Iap antagonists patent thumbnailnew patent Iap antagonists
There are disclosed compounds that modulate the activity of inhibitors of apoptosis (iaps), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.. .
Bristol-myers Squibb Company


08/27/15
20150238475 
 Inhibition of quorum sensing-mediated processes in bacteria patent thumbnailnew patent Inhibition of quorum sensing-mediated processes in bacteria
Methods are provided for identifying molecules that can be used to positively and negatively manipulate quorum-sensing-mediated communication to control bacterial behavior. Small-molecule antagonists that disrupt quorum-sensing-mediated activities are identified.
The Trustees Of Princeton University


08/27/15
20150238470 
 Muscarinic acetylcholine receptor antagonists patent thumbnailnew patent Muscarinic acetylcholine receptor antagonists
Methods of using muscarinic acetylcholine receptor antagonists are provided.. .
Glaxo Group Limited


08/20/15
20150233925 

Assays and cell-based tests using a receptor na/k-atpase/src complex and uses thereof


Described herein are assays and complementary cell culture based tests, and uses thereof for determining agonists or antagonists of na/k-atpase/src complex, and methods of treatment therewith.. .
The University Of Toledo


08/20/15
20150232471 

Novel n-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders


And their use in therapeutic treatments.. .

08/20/15
20150232468 

Cbp/catenin antagonists for enhancing asymmetric division of somatic stem cells


Provided are: composition and methods for: treating aging or an age-related condition, symptom or disease; stimulating hair growth, regrowth or pigmentation (or preventing hair loss); for increasing the expression of an adenosine receptor in dermal cells (in combination with hair growth); for treating a condition or disease of the skin or at least one symptom thereof, including cosmetic treatment (e.g., wrinkles, hyperpigmentation, redness, rosacea, dryness, cracking, loss of firmness, loss of elasticity, thinning, and loss of vibrance). The methods comprise administering a sufficient amount of the disclosed cbp/catenin (e.g., cbp/b-catenin) antagonist compositions, and particularly wherein administration is in an amount and manner sufficient to provide for increasing the number of asymmetric renewing divisions relative to, or at the expense of symmetric divisions in relevant somatic stem cell population.
University Of Southern California


08/20/15
20150232448 

6-piperazinyl-3,4-dihydroquinazolin-2(1h)-ones


A series of new 6-piperazinyl-3,4-dihydroquinazolin-2(1h)-ones have been synthesized. The compounds are structurally related to adoprazine, a potential atypical antipsychotics bearing potent d2 receptor antagonist and 5-ht1a receptor agonist properties.
King Fahd University Of Petroleum And Minerals


08/20/15
20150232435 

Urea and amide derivatives of aminoalkylpiperazines and use thereof


Provided are compounds represented by the formula: with y, ri, and r2 being defined in the present disclosure; pharmaceutically acceptable salts thereof, deuterated forms thereof, isomers thereof, solvates thereof, and mixtures thereof. The compounds can be used for treating a patient suffering from a condition capable of treatment with a partial agonist or antagonist of the dopamine d2/d3 receptors and are especially useful for patients suffering from schizophrenia, depressions, neurodegenerative diseases such as parkinson's, dyskinesias, substance abuse and relapse to substance abuse and addiction to substances such as cocaine, methamphetamine, nicotine and alcohol, glaucoma, cognitive disorders, restless leg syndrome, attention deficit hyperactivity disorders, hyperprolactinemia, autism, motor disturbances such as akathisia, rigor, dystonias as well as various disorders of the urinary tract and other neurologic disorders.
Southern Research Institute


08/20/15
20150231336 

Medicament delivery device for administration of opioid antagonists including formulations for naloxone


Medicament delivery devices for administration of opioid antagonists are described herein. In some embodiments, an apparatus includes a housing, a medicament container disposed within the housing and an energy storage member disposed within the housing.
Kaleo, Inc.


08/20/15
20150231215 

Vista antagonist and methods of use


The present invention is directed to a peptide, multimer, conjugate, analog, derivative or mimetic thereof that inhibits the activity of vista. The invention further contemplates therapeutic use of the vista antagonist peptide, multimer, conjugate, derivative or mimetic thereof, including treating or preventing cancer, bacterial infections, viral infections, parasitic infections and fungal infections, as well as research uses of the antagonist..

08/20/15
20150231127 

Bitopic muscarinic agonists and antagonists and methods of synthesis and use thereof


Compositions for treating a condition associated with activity of a muscarinic receptor (e.g., one or more of m1, m2, m3, m4, m5) and for anesthetizing a subject include a bitopic muscarinic antagonist or agonist. A bitopic muscarinic antagonist named jb-d4 was discovered.
Barry University, Inc.


08/20/15
20150231126 

Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics


Combinations of 5-ht2a inverse agonists or antagonists such as pimavanserin with antipsychotics such as risperidone are shown induce a rapid onset of antipsychotic action and increase the responders when compared to therapy with the antipsychotic alone. These effects can be achieved at a low dose of the antipsychotic, thereby reducing the incidence of side effects.
Acadia Pharmaceuticals Inc.


08/20/15
20150231086 

Tamper-resistant oral opioid agonist formulations


Oral dosage forms containing an opioid antagonist in a sequestered form are described. The opioid antagonist is sequestered such that it is not released or substantially not released in the gastrointestinal tract from the dosage form which is administered orally intact.
Purdue Pharma L.p.


08/13/15
20150225790 

Methods for identifying subjects with an increased likelihood of responding to ccr1 antagonist


The invention describes a method for identifying subjects with an increased likelihood of responding to treatments that modulate chemokine or chemokine receptor activity by measuring the change in expression of immune mediated genes.. .
Bristol-myers Squibb Company


08/13/15
20150225698 

In vitro pancreatic differentiation of pluripotent mammalian cells


This invention relates to the in vitro differentiation of pluripotent cells into pancreatic progenitors by i) culturing pluripotent cells in a definitive endoderm (de) medium comprising a tgfp ligand, fibroblast growth factor (fgf), bone morphogenetic protein (bmp), a pi3k inhibitor and optionally a gsk3 β inhibitor to produce a population of definitive endoderm cells, ii) culturing the definitive endoderm cells in a first pancreatic medium comprising an activin antagonist; fgf; retinoic acid; and a bmp inhibitor to produce a population of dorsal foregut cells; iii) culturing the dorsal foregut cells in a second pancreatic medium comprising fgf, retinoic acid, a bmp inhibitor, and a hedgehog signalling inhibitor, and; iv) culturing the endoderm cells in a third pancreatic medium comprising fgf. The progenitor cells thus produced may be further differentiated into pancreatic endocrine cells.
Cambridge Enterprise Limited


08/13/15
20150225476 

Method for treating a disease or disorder of the lung by inhibition of the hedgehog pathway


The present invention is directed to a method of treating a disease or disorder characterised by one or more of the following: decreased lung function, bronchial hyper-responsiveness, hypersecretion of mucus, epithelial cell hyperplasia, smooth muscle hypertrophy, fibrosis or inflammation with an antagonist of a hedgehog protein, an antagonist of smoothened, or an antagonist of gli. The present invention further provides kits for implementing the above method and the use of an antagonist of a hedge-hog protein, an antagonist of smoothened, or an antagonist of gli for treating the above disease or disorder..
Agency For Science, Technology And Research


08/13/15
20150225452 

Iap antagonists


There are disclosed compounds of formula (i) that modulate the activity of inhibitors of apoptosis (iaps), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing said compounds.. .
Bristol-myers Squibb Company


08/13/15
20150225385 

Ethynyl derivatives


It has now surprisingly been found that the compounds of general formula i are metabotropic glutamate receptor antagonists (negative allosteric modulators) for use in the treatment of anxiety and pain, depression, fragile-x syndrom, autism spectrum disorders, parkinson's disease, and gastroesophageal reflux disease (gerd).. .

08/13/15
20150225381 

Imidazoline derivatives, preparation methods thereof, and their applications in medicine


Preparation methods thereof, pharmaceutical compositions comprising such derivatives, and applications of such derivatives in preparing androgen receptor antagonists and medicaments for treating diseases such as prostate cancer are described.. .

08/13/15
20150225345 

Ethynyl derivatives


It has now surprisingly been found that the compounds of general formula i are metabotropic glutamate receptor antagonists (negative allosteric modulators) for use in the treatment of anxiety and pain, depression, fragile-x syndrom, autism spectrum disorders, parkinson's disease, and gastroesophageal reflux disease (gerd).. .

08/13/15
20150225344 

Ethynyl derivatives


It has now surprisingly been found that the compounds of general formula i are metabotropic glutamate receptor antagonists (negative allosteric modulators) for use in the treatment of anxiety and pain, depression, fragile-x syndrome, autism spectrum disorders, parkinson's disease, and gastroesophageal reflux disease (gerd).. .

08/13/15
20150224191 

Combination treatment with vegf-c antagonists


The invention relates to a method and kit for treating cancer in a human subject, the method comprising administering to the subject in combination therapeutically effective amounts of a vegf-c antagonist and an anti-neoplastic composition, and the kit comprising a vegf-c antagonist for administering to the subject in combination with an anti-neoplastic composition. The invention further relates to methods for: increasing the duration of survival of, increasing the progression-free survival of, increasing the duration of response of, or treating, a subject or a group of human subjects susceptible to or diagnosed as having a cancer; or treating a human subject or a group of human subjects having metastatic colorectal cancer, prostate cancer, pancreatic cancer or glioblastoma, the methods comprising administering to the subject or subjects in the group in combination effective amounts of a vegf-c antagonist and an anti-neoplastic composition..
Vegenics Pty Limited


08/13/15
20150224095 

Use of non-peptidic nk1 receptor antagonists for the production of apoptosis in tumor cells


Substance p antagonists and, in particular, non-peptidic nk1 receptor antagonists are useful for the treatment of cancer and, more specifically, human melanoma, neuroblastoma, glioma, human hodgkin's lymphoma km-h2, lymphoblastic leukemia, human rhabdomyosarcoma, human breast carcinoma, human burkitt's lymphoma, human lung carcinoma, human ewing's sarcoma, human glioma and human osteosarcoma.. .
Antagonista Enekauno, S.l.


08/13/15
20150223472 

Increasing plant yield with bacterial/fungal combinations


A seed treated with a fungal/bacterial antagonist combination and a seed assembly comprising a seed and a fungal/bacterial antagonist combination. The fungal/bacterial antagonist combination comprises a trichoderma virens fungal antagonist and a bacillus amyloliquefaciens bacterial antagonist for controlling plant pathogens as a biocontrol agent, bio-pesticide or bio-fungicide.
Novozymes Bioag A/s


08/06/15
20150218563 

Compositions and methods for modulation of rorgammat functions


The present invention relates to expression of rorγt in cells and tissues and the effect of expression of this gene on proliferation of specific immune cells and in promotion of immune cell aggregates and in induction of il17 producing cells. Furthermore, the invention relates to methods and agents that may decrease function of the gene product (the protein) or expression of this gene in individuals experiencing an inflammatory condition, an autoimmune disease or a food allergy, or any other condition whereby it is desirable to inhibit an immune response.

08/06/15
20150218523 

Manufacture of vascular smooth muscle cells and the use


A method for preparing brain-specific vascular smooth muscle cells comprising the step of: (a) contacting a population of stem cells with a composition comprising a bone morphogenetic protein (bmp) antagonist, a fibroblast growth factor (fgf) and an activin or nodal inhibitor to produce a population of neural crest cells.. .
Agency For Science, Technology And Research


08/06/15
20150218249 

Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis


The present invention provides materials and methods for antagonizing the function of vascular endothelial growth factor receptors, platelet derived growth factor receptors and other receptors, to prevent, inhibit, or ameliorate allograft rejection or arteriosclerosis in organisms that receive an organ transplant.. .
Vegenics Pty Limited


08/06/15
20150218239 

Fcrn antagonists and methods of use


Provided are novel fcrn antagonist compositions comprising a variant fc region that binds specifically to fcrn with increased affinity and reduced ph dependence relative to the native fc region. Also provided are fcrn antagonists with enhanced cd16 binding affinity.
The Board Of Regents Of The University Of Texas System


08/06/15
20150218172 

Pyrrolo[2,3-d]pyrimidine tropomyosin-related kinase inhibitors


And their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as trk antagonists.. .

08/06/15
20150218144 

Substituted phenylcarbamate compounds


And pharmaceutically acceptable salts thereof, wherein y, r1, r2 and r3 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (i) as well as pharmaceutical compositions containing such compounds.

08/06/15
20150218143 

Sulfonamide compounds having trpm8 antagonistic activity


Other symbols are the same as defined in the specification.. .

08/06/15
20150218141 

Substituted carbamate compounds


And pharmaceutically acceptable salts thereof, wherein y, r1 and r3 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (i) as well as pharmaceutical compositions containing such compounds.

08/06/15
20150218133 

6-aminoindole derivatives as trp channel antagonists


And pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (i) as well as pharmaceutical compositions containing such compounds.

08/06/15
20150218093 

Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists


The present invention provides compounds of formula (i): as defined in the specification and compositions comprising any of such novel compounds. These compounds are melanin concentrating hormone receptor-1 (mchr1) antagonists which may be used as medicaments..
Bristol-myers Squibb Company


08/06/15
20150218092 

Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists


The present invention provides compounds of formula (i): as defined in the specification and compositions comprising any of such novel compounds. These compounds are melanin concentrating hormone receptor-1 (mchr1) antagonists which may be used as medicaments..
Bristol-myers Squibb Company


08/06/15
20150217006 

Al-f-18-labeled, al-f-19-labeled and ga-68-labeled gastrin-releasing peptide receptor (grpr)-antagonists for imaging of prostate cancer


The present application discloses compositions and methods of synthesis and use of 18f-, 19f- or 68ga-labeled molecules of use in pet, spect and/or mri imaging of prostate cancer. Preferably, the 18f, 19f or 68ga is attached to a chelator moiety on a prostate cancer targeting molecule, more preferably a bombesin analog, more preferably a grpr antagonist, most preferably jmv5132 or jmv4168.
Immunomedics, Inc.


08/06/15
20150216970 

Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors


The present invention describes combination treatment comprising a pd-1 axis binding antagonist and an agent that decreases or inhibits tigit expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.. .
Genentech, Inc.


08/06/15
20150216891 

Nucleic acids targeting tctp for use in the treatment of chemo-or hormone- resistant cancers


The present invention concerns a tctp antagonist, in particular a nucleic acid targeting an m rna encoding translationally-controlled tumor protein (tctp), wherein said nucleic acid is capable of reducing the amount of tctp in cells, for use in the treatment or prevention of hormone-independent cancer or chemo-resistant cancer, such as an androgen-independent prostate cancer.. .
Universite De La Meditarranee Aix-marseille Ii


08/06/15
20150216875 

Modulating the production of neurons and/or oligodendrocytes from white matter progenitor cells


The present invention relates to a method of modulating production of neurons and/or oligodendrocytes from neural progenitor cells of human white matter and to a method of treating a subject for a condition modulated by underproduction of oligodendrocytes from human white matter. Both of these methods involve administering an agonist or antagonist of one or more molecules set forth in tables 1 and/or 2 to the neural progenitor cells.
Cornell Research Foundation, Inc.


08/06/15
20150216857 

Compositions and methods for treatment


The present invention provides compounds and methods for the treatment of lfa-1 mediated diseases. In particular, lfa-1 antagonists are described herein and these antagonists are used in the treatment of lfa-1 mediated diseases.
Sarcode Bioscience Inc.


08/06/15
20150216833 

Therapeutic for treating inflammatory lung disorders


A calcium/cation-sensing receptor (casr) antagonist to treat an inflammatory lung disorder is described. Methods of treatment including the antagonist, combination therapeutics including the antagonist and at least one other agent, and nebulisers or inhalers including the antagonist are also described..
King's College London


07/30/15
20150211073 

Mrna-based gene expression for personalizing patient cancer therapy with an mdm2 antagonist


Use of at least an mdm2 gene panel, preferably a four gene mdm2 gene panel, as a biomarker for predicting the response to a mdm2 antagonist.. .
Hoffmann-la Roche Inc.


07/30/15
20150210772 

Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody


The present invention describes combination treatment comprising a pd-1 axis binding antagonist and an anti-cd20 antibody and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.. .
Genentech, Inc.


07/30/15
20150210767 

Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists


The invention relates to storage-stable anti-tnfr1 antibody single variable domains (dabs), antagonists and multispecific ligands, as well as methods and uses of these. The anti-tnfr1 polypeptides, antibody single variable domains (dabs), antagonists and multispecific ligands are useful for treating and/or preventing inflammatory disease, such as arthritis or copd, as well as for pulmonary administration, oral administration, delivery to the lung and delivery to the gi tract of a patient..
Glaxo Group Limited


07/30/15
20150210689 

Antagonists acting at multiple prostaglandin receptors for the treatment of inflammation


Compounds, processes for their preparation, pharmaceutical compositions containing such compounds and their use in treating therapeutic conditions, in particular conditions mediated by the action of ligands on the fp, dp, ep1, ep4, ip, dp1, fp and tp prostaglandin (pg) receptors thereby providing a general anti-inflammatory response.. .
Allergan, Inc.


07/30/15
20150210649 

Process for preparation of androgen receptor antagonist


The present invention provides an isopropanol solvate of enzalutamide. The present invention also provides a process for the preparation of androgen receptor antagonist.
Cadila Healthcare Limited


07/30/15
20150209426 

Treatment of cancer


A method for treating breast cancer with an insulin-like growth factor (igf) receptor antagonist in combination with exemestane and everolimus.. .
Boehringer Ingelheim International Gmbh


07/30/15
20150209359 

Combination therapies and methods of use thereof for treating cancer


Pharmaceutical compositions including an effective amount of an antiandrogen or androgen antagonist in combination with a plk inhibitor and methods of use thereof for treating cancer are disclosed. Administration of the combination of the active agents can be effective to reduce cancer cell proliferation or viability in a subject with cancer to the same degree, or a greater degree than administering to the subject the same amount of either active agent alone.
Massachusetts Institute Of Technology


07/30/15
20150209353 

Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome


Methods for treating down syndrome and improving cognitive function of a patient with an intellectual disability are disclosed. 5-hydroxytryptamine sub-receptor six (5-ht6) receptor antagonists are provided for improving the cognition of a down syndrome patient..
The University Of Utah Research Foundation


07/30/15
20150209348 

Histamine 4 receptor partial agonists, inverse agonists or antagonists for use in treating non-autoimmune uveitis


The invention provides a compound which is a histamine 4 receptor antagonist, partial agonist or inverse agonist, for use in the treatment of non-autoimmune uveitis. The compound preferably has a structural core comprising a substituted pyrimidine group, such as an aminopyrimidine, diaminopyrimidine or triaminopyrimidine group, a thienopyrimidine, a furopyrimidine, a benzimidazole, an aryl or heteroaryl-fused pyrimidine, an indole, a bicyclic heteroaryl-substituted imidazole or a quinazoline group..
Ucl Business Plc


07/30/15
20150209311 

(r,r) formoterol in combination with other pharmacological agents


This invention related to methods of treating, preventing and managing various pulmonary diseases or disorders using stereomerically pure (r,r)-formoterol in combination with other pharmacological agents such as leukotriene inhibitors and neurokinin receptor antagonists. Pharmaceutical compositions comprising (r,r)-formoterol and other pharmacological agents are also disclosed..
Sunovion Pharmaceuticals Inc.


07/23/15
20150204892 

Methods and compositions for diagnosis and prognosis of renal injury and renal failure


The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more biomarkers selected from the group consisting of tumor necrosis factor receptor superfamily member 10b, cadherin-16, caspase-9, bcl2 antagonist of cell death, caspase-1, cadherin-1, poly [adp-ribose] polymerase 1, cyclin-dependent kinase inhibitor 1, cadherin-5, myoglobin, apolipoprotein a-ii, mucin-16, carcinoembryonic antigen-related cell adhesion molecule 5, and cellular tumor antigen p53 as diagnostic and prognostic biomarker assays in renal injuries..
Astute Medical, Inc.


07/23/15
20150203819 

Production of red blood cells and platelets from stem cells


This disclosure provides methods of making a megakaryocyte-erythroid progenitor cell (mep), comprising differentiating a mep precursor cell into a mep in culture in the presence of an aryl hydrocarbon receptor (ahr) modulator. In some embodiments the ahr modulator is an ahr antagonist.
Trustees Of Boston University


07/23/15
20150203585 

Use of dr6 and p75 antagonists to promote survival of cells of the nervous system


The present invention relates to death receptor-6 (dr6) proteins which are members of the tumor necrosis factor (tnf) receptor family, and have now been shown to be important for regulating apoptosis in cells of the nervous system. In addition, it has been discovered that p75 is a ligand for dr6.
Biogen Idec Ma Inc.


07/23/15
20150203496 

Aliphatic spirolactam cgrp receptor antagonists


The present invention is directed to aliphatic spirolactam derivatives which are antagonists of cgrp receptors and useful in the treatment or prevention of diseases in which cgrp is involved, such as migraine. The invention is also directed to pharmaceutical\compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which cgrp is involved..
Merck Sharp & Dohme Corp.


07/23/15
20150203452 

Piperidinium quaternary salts


There are described new 1-alkyl-1-methyl-4-[(2,2-diphenyl-2-propoxy)acetoxy]piperidinium halides and pharmaceutical compositions comprising a 1-alkyl-1-methyl-4-[(2,2-diphenyl-2-propoxy)acetoxy]piperidinium halide as an active ingredient. These products are non-selective muscarinic acetylcholine receptor antagonists acting in the periphery and not in the brain..
Chase Pharmaceuticals Corporation


07/23/15
20150202297 

Dry powder inhalers comprising a carrier other than lactose and a ternary component


This invention relates to novel pharmaceutical compositions for inhalation comprising separately, sequentially or together, drugs having amine in the form of a dry powder in admixture with a pharmaceutically acceptable carrier, other than lactose, and its use in the treatment of respiratory condition selected from asthma and chronic obstructive pulmonary disease (copd) and other obstructive airways diseases. More particularly, the invention relates to pharmaceutical composition for inhalation further comprising a ternary component.
Arven Ilac Sanayi Ve Ticaret Anonim Sirketi


07/23/15
20150202289 

Combination therapy for the treatment of ocular neovascular disorders


The invention features methods for treating a patient diagnosed with, or at risk of developing, a neovascular disorder by administering a pdgf antagonist and a vegf antagonist to the patient. The invention also features a pharmaceutical composition containing a pdgf antagonist and a vegf antagonist for the treatment or prevention of a neovascular disorder..
Ophthotech Corporation


07/23/15
20150202288 

Combination therapy for the treatment of ocular neovascular disorders


The invention features methods for treating a patient diagnosed with, or at risk of developing, a neovascular disorder by administering a pdgf antagonist and a vegf antagonist to the patient. The invention also features a pharmaceutical composition containing a pdgf antagonist and a vegf antagonist for the treatment or prevention of a neovascular disorder..
Ophthotech Corporation


07/23/15
20150202259 

Targeted oesophageal administration of zn-alpha2-glycoproteins (zag), methods and formulations thereof


The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as hypoglycemia, obesity, diabetes, and the like by targeted administration to the oesphagus of a subject of zn-α2-glycoproteins or a functional fragment thereof, alone or in combination with additional agents, such as β adrenergin receptor agonists, β adrenergin receptor antagonists, and/or glycemic control agents.. .
Aston University


07/23/15
20150202213 

Combinations comprising antimuscarinic agents and corticosteroids


Combinations comprising (a) a corticosteroid and (b) an antagonist of m3 muscarinic receptors which is 3(r)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion x, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary disease.. .

07/23/15
20150202199 

Treatments for depression and other diseases with a low dose agent


The present invention relates to improved compositions and methods for the treatment or prevention of various diseases, including forms of depression, including, for example, breakthrough depression and treatment-refractory depression, and other mood disorders, as well as parkinson's disease, bipolar disorder, bipolar disorder, attention deficit disorder (adhd), restless leg syndrome (rls), and obesity. In some embodiments, the compositions and methods comprise low dose naltrexone or related opioid antagonists..
Pharmorx Therapeutics, Inc.


07/23/15
20150202148 

Dry powder inhalers comprising a carrier other than lactose


This invention relates to novel pharmaceutical compositions for inhalation comprising separately, sequentially or together, drugs having amine in the form of a dry powder in admixture with a pharmaceutically acceptable carrier, other than lactose, and its use in the treatment of respiratory condition selected from asthma and chronic obstructive pulmonary disease (copd) and other obstructive airways diseases. In addition, the present invention relates to novel pharmaceutical composition for inhalation based on combinations of long acting muscarinic antagonists, long acting beta agonists, short acting beta-2 agonists, corticosteroids or a combination of two or more of them..
Arven Llac Sanayi Ve Ticaret Anonim Sirketi


07/16/15
20150197574 

Use of transferrin receptor antagonist for the treatment of thalassemia


The present disclosure relates to antagonists of transferrin receptor and compositions and methods of use of said antagonists for treating pathological disorders such as thalassemia disorders. .
Universite Paris Diderot - Paris 7


07/16/15
20150197566 

Polynucleotides encoding antagonists of il-17a, il-17f, and il-23p19


The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of il-17a, il-17f, and il-23. Antagonists include antibodies and antibody fragments that bind il-23 and that bind il-17a or il-17f, such as antibodies that are cross-reactive for il-17a and il-17f.
Zymogenetics, Inc.


07/16/15
20150197563 

Notch binding agents and antagonists and methods of use thereof


The present invention relates to notch-binding agents and notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human notch receptor, such as notch2 and/or notch3, and inhibit tumor growth.
Oncomed Pharmaceuticals, Inc.


07/16/15
20150197560 

Humanized anti-beta7 antagonists and uses therefor


The invention provides therapeutic anti-beta7 antibodies, compositions comprising, and methods of using these antibodies.. .
Genentech, Inc.


07/16/15
20150197521 

Amino-heteroaryl 7-hydroxy-spiropiperidine indolinyl antagonists of p2y1 receptor


The present invention provides compounds of formula (i): as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of p2y1 receptor which may be used as medicaments..
Bristol-myers Squibb Company


07/16/15
20150197506 

Novel benzopyran compounds, compositions and uses thereof


Benzopyran compounds with strong anti-estrogenic activity and essentially no estrogenic activity are provided, which are op-1038, which is 3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3r)-3-methylpyrrolidin-1-yl]ethoxy}phenyl)-2h-chromen-7-ol, and op-1074, which is (2s)-3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3r)-3-methylpyrrolidin-1-yl]ethoxy}phenyl)-2h-chromen-7-ol. Op-1074 is a pure anti-estrogen when tested in the agonist mode and a complete anti-estrogen when tested in the antagonist mode.
Olema Pharmaceuticals, Inc.


07/16/15
20150197490 

Crystalline polymorphic forms of an antidiabetic compound


This compound is useful as a glucagon receptor antagonist and serves as a pharmaceutically active ingredient for the treatment of type 2 diabetes and related conditions, such as hyperglycemia, obesity, dyslipidemia, and the metabolic syndrome. Hydrates, hemihydrates, anhydrates and similar polymorphic forms are included..

07/09/15
20150191540 

Preventive or therapeutic agent for sensitized t cell-mediated diseases comprising il-6 antagonist as an active ingredient


A preventive or therapeutic agent for sensitized t cell-mediated diseases comprising an interleukin-6 (il-6) antagonist, for example an antibody directed against il-6 receptor, an antibody directed against il-6, an antibody directed against gp130, and the like.. .
Chugai Seiyaku Kabushiki Kaisha


07/09/15
20150191487 

Tetrazole-substituted arylamides as p2x3 and p2x2/3 antagonists


Or a pharmaceutically acceptable salt thereof, wherein, r1 is optionally substituted tetrazolyl, r2 is optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and r3, r4, r5 and r6 are as defined herein. Also provided are methods of using the compounds for treating diseases associated with the p2x3 and/or a p2x2/3 receptor antagonist and methods of making the compounds..

07/09/15
20150191452 

Selective nr2b antagonists


The disclosure generally relates to compounds of formula i, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the nr2b receptor and may be useful for the treatment of various disorders of the central nervous system..
Bristol-myers Squibb Company


07/09/15
20150191435 

Dual-acting imidazole antihypertensive agents


Wherein: ar, r, r2-3, x, and r5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have at1 receptor antagonist activity and neprilysin inhibition activity.

07/09/15
20150191431 

N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products


The invention relates to n-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides, intermediates and methods for their production, use thereof for treating and/or preventing diseases and use thereof for producing medicinal products and use thereof for treating and/or preventing diseases, especially of hyperproliferative diseases.. .
Bayer Pharma Aktiengesellschaft


07/09/15
20150191426 

Methods and compositions for oral delivery of fts


Disclosed are oral dosage forms containing a ras antagonist including fts and structural analogs thereof, and at least one pharmaceutically acceptable excipient other than a cyclodextrin, and methods of orally administering same to treat diseases and disorders responsive to the ras antagonists.. .
Concordia Pharmaceuticals, Inc.


07/09/15
20150190523 

Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation


A pharmaceutical composition comprising a phosphatidylcholine-based opioid receptor antagonist formulation, as well as methods of their use and methods of their preparation are provided herein. Such pharmaceutical composition may be used for treating and preventing opioid-induced side effects in patients, and may be provided to chronic opioid users as well..
The University Of Chicago


07/09/15
20150190506 

Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists


The invention provides compositions and methods for treating cancers. The method comprises administering a pd-1 axis binding antagonist and an ox40 binding agonist..
Genentech, Inc.


07/09/15
20150190472 

Use of the angiotensin-(1-9) peptide or derivatives thereof, use of vectors overexpressing the ace2 enzyme that produces angiotensin-(1-9) for preparing medicaments useful for preventing, reverting, inhibiting and/or reducing hypertension and/or inducing vasodilation


The present invention is related to the use of the angiotensin-(1-9) peptide or peptides derived therefrom, which are biological or chemical analogues, for preparing medicaments useful for preventing, reverting, inhibiting and/or reducing hypertension and/or inducing vasodilation. Furthermore, this invention also comprises a vector overexpressing the homologous angiotensin-ii converting enzyme (ace2) for elevating the concentration in the blood and/or tissues of the angiotensin-(1-9) peptide.
Universidad De Chile


07/09/15
20150190402 

Solid dosage formulations of an orexin receptor antagonists


The present invention is directed to a pharmaceutical composition comprising the compound suvorexant, or a pharmaceutically acceptable salt thereof, a concentration-enhancing polymer, and optionally a pharmaceutically acceptable surfactant. The concentration-enhancing polymer is a polymer that forms an amorphous dispersion with suvorexant, that is insoluble or almost completely insoluble in water by (a) dissolving the suvorexant or (b) interacting with the suvorexant in such a way that the suvorexant does not form crystals or crystalline domains in the polymer.
Merck Sharp & Dohme Corp.


07/09/15
20150190399 

New differential-release pharmaceutical composition containing three active principles


This invention relates to a differential release formulation containing an angiotensin-ii receptor antagonist, a calcium channel blocker and a diuretic, wherein the said pharmaceutical composition allows the sequential administration of the active principles in a single dose based on the treatment needs.. .
Landsteiner Scientific S.a. De C.v.




Popular terms: [SEARCH]

Antagonist topics: Antagonist, Recurrence, Proliferative Disorder, Proliferative, Antibodies, Progesterone, Dicyclomine, Scopolamine, Extracellular, Pharmaceutically Acceptable Salt, Metalloprotein, Nucleic Acids, Polynucleotide, Nucleic Acid, Monoclonal

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Antagonist for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Antagonist with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.7595

4779

459671 - 0 - 103